Prevalence of disease related prion protein in anonymous tonsil specimens in Britain: cross sectional opportunistic survey

Objective To establish with improved accuracy the prevalence of disease related prion protein (PrPCJD) in the population of Britain and thereby guide a proportionate public health response to limit the threat of healthcare associated transmission of variant Creutzfeldt-Jakob disease (vCJD). Design Cross sectional opportunistic survey. Study samples Anonymised tonsil pairs removed at elective tonsillectomy throughout England and Scotland. Setting National anonymous tissue archive for England and Scotland. Main outcome measure Presence of PrPCJD determined by using two enzyme immunoassays based on different analytical principles, with further investigation by immunohistochemistry or immunoblotting of any samples reactive in either assay. Results Testing of 63 007 samples was completed by the end of September 2008. Of these, 12 753 were from the birth cohort in which most vCJD cases have arisen (1961-85) and 19 908 were from the 1986-95 cohort that would have been also exposed to bovine spongiform encephalopathy through infected meat or meat products. None of the samples tested was unequivocally reactive in both enzyme immunoassays. Only two samples were reactive in one or other enzyme immunoassay and equivocal in the other, and nine samples were equivocally reactive in both enzyme immunoassays. Two hundred and seventy six samples were initially reactive in one or other enzyme immunoassay; the repeat reactivity rate was 15% or less, depending on the enzyme immunoassay and cut-off definition. None of the samples (including all the 276 initially reactive in enzyme immunoassay) that were investigated by immunohistochemistry or immunoblotting was positive for the presence of PrPCJD. Conclusions The observed prevalence of PrPCJD in tonsils from the 1961-95 combined birth cohort was 0/32 661 with a 95% confidence interval of 0 to 113 per million. In the 1961-85 cohort, the prevalence of zero with a 95% confidence interval of 0 to 289 per million was lower than, but still consistent with, a previous survey of appendix tissue that showed a prevalence of 292 per million with a 95% confidence interval of 60 to 853 per million. Continuing to archive and test tonsil specimens, especially in older birth cohorts, and other complementary large scale anonymous tissue surveys, particularly of post-mortem tissues, will further refine the calculated prevalence of PrPCJD.

[1]  J. Berger.  Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report , 2008 .

[2]  F. V. van Zijderveld,et al.  Pathogenesis of bovine spongiform encephalopathy in sheep , 2007, Archives of Virology.

[3]  Declan King,et al.  High Titers of Transmissible Spongiform Encephalopathy Infectivity Associated with Extremely Low Levels of PrPSc in Vivo* , 2007, Journal of Biological Chemistry.

[4]  Suvankar Pal,et al.  Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report , 2006, The Lancet.

[5]  R. Castellani,et al.  Classification of sporadic Creutzfeldt-Jakob disease revisited. , 2006, Brain : a journal of neurology.

[6]  James W Ironside,et al.  Variant Creutzfeldt-Jakob disease: prion protein genotype analysis of positive appendix tissue samples from a retrospective prevalence study , 2006, BMJ : British Medical Journal.

[7]  J. Bogousslavsky,et al.  Analysis of Prion Strains by PrPSc Profiling in Sporadic Creutzfeldt–Jakob Disease , 2005, PLoS medicine.

[8]  J. Langeveld,et al.  Immunopathology and Infectious Diseases Detection of Type 1 Prion Protein in Variant Creutzfeldt-Jakob Disease , 2005 .

[9]  Patrick Tremblay,et al.  Prion clearance in bigenic mice. , 2005, The Journal of general virology.

[10]  Paul Clarke,et al.  Projections of the future course of the primary vCJD epidemic in the UK: inclusion of subclinical infection and the possibility of wider genetic susceptibility , 2005, Journal of The Royal Society Interface.

[11]  Lorraine C. Smith,et al.  Analysis of 2000 consecutive UK tonsillectomy specimens for disease-related prion protein , 2004, The Lancet.

[12]  Mark Head,et al.  Preclinical variant CJD after blood transfusion in a PRNP codon 129 heterozygous patient , 2004 .

[13]  M. Head,et al.  Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient , 2004, The Lancet.

[14]  Mark Penney,et al.  Prevalence of lymphoreticular prion protein accumulation in UK tissue samples , 2004, The Journal of pathology.

[15]  J. Ironside,et al.  Prion protein heterogeneity in sporadic but not variant Creutzfeldt–Jakob disease: U.K. cases 1991–2002 , 2004, Annals of neurology.

[16]  C. Wiley,et al.  Specificity of lymphoreticular accumulation of prion protein for variant Creutzfeldt–Jakob disease , 2004, Journal of Clinical Pathology.

[17]  J Mackenzie,et al.  Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion , 2004, The Lancet.

[18]  W. Nailon,et al.  Peripheral tissue involvement in sporadic, iatrogenic, and variant Creutzfeldt-Jakob disease: an immunohistochemical, quantitative, and biochemical study. , 2004, The American journal of pathology.

[19]  H. Budka,et al.  Molecular classification of sporadic Creutzfeldt-Jakob disease. , 2003, Brain : a journal of neurology.

[20]  J. Collinge,et al.  Molecular and clinical classification of human prion disease. , 2003, British medical bulletin.

[21]  Michael P H Stumpf,et al.  Balancing Selection at the Prion Protein Gene Consistent with Prehistoric Kurulike Epidemics , 2003, Science.

[22]  J. Collinge,et al.  Cytokine profiles in HIV seropositive patients with tuberculous meningitis , 2002, Journal of neurology, neurosurgery, and psychiatry.

[23]  J. Ironside,et al.  Pathological diagnosis of variant Creutzfeldt‐Jakob disease , 2002, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[24]  J. Ironside,et al.  Detection of variant Creutzfeldt-Jakob disease infectivity in extraneural tissues , 2001, The Lancet.

[25]  J. Collinge,et al.  Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay , 2001, The Lancet.

[26]  H. Schwarz,et al.  Genotyping of the prion protein gene at codon 129 , 1999, Acta Neuropathologica.

[27]  P. Brown,et al.  Natural and experimental oral infection of nonhuman primates by bovine spongiform encephalopathy agents. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[28]  J Collinge,et al.  Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples , 1999, The Lancet.

[29]  J. Zajicek,et al.  Prion immunoreactivity in appendix before clinical onset of variant Creutzfeldt-Jakob disease , 1998, The Lancet.

[30]  DavidJ. Evans,et al.  Diagnosis of new variant Creutzfeldt-Jakob disease by tonsil biopsy , 1997, The Lancet.

[31]  A. Giese,et al.  Polymorphism at codon 129 of the prion protein gene determines cerebellar pathology in Creutzfeldt-Jakob disease. , 1996, Clinical neuropathology.

[32]  E. Broussolle,et al.  New variant of Creutzfeldt-Jakob disease in a 26-year-old French man , 1996, The Lancet.

[33]  John Collinge,et al.  Homozygous prion protein genotype predisposes to sporadic Creutzfeldt–Jakob disease , 1991, Nature.